Despite high-dose chemotherapy, her day +30 marrow demonstrated relapsed BL—she was given rituximab–polatuzumab and underwent apheresis for anti-CD19 CAR-T therapy (lisocabtagene maraleucel). This evidence concerns the gene CD19 and Burkitt lymphoma.